JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

# MONITORING ADVERSE DRUG REACTIONS (ADRS) AND RISK-BENEFIT ASSESSMENT

**Prathamesh.T.Patil[1], Sandesh.U.Sutar[2], Gururaj.D.Patil[3],Shubham.S.More[4], Tejashree.S.Khamkar[5]**

[1234] Department of PharmacyAshokrao Mane College of Pharmacy,PethVadgaon/Shivaji University 416112,Maharashtra, India

[5] Department of Pharmaceutical Chemistry, Assistant Professor, Ashokrao Mane College of Pharmacy, Peth Vadgaon/Shivaji University 416112, Maharashtra, India

**ABSTRACT:**

Unintentional and dangerous reactions to drugs, known as adverse drug reactions (ADRs), present serious risks to patient safety and raise morbidity, mortality, and healthcare expenses globally. Pharmacovigilance is crucial for directing therapeutic choice and regulatory oversight, and it includes tracking adverse drug reactions (ADRs) and conducting systematic risk-benefit analyses. Inadvertent or slow signal detection, and inadequate coverage of everyday populations are the drawbacks of traditional ADR detection techniques, such as clinical trials and spontaneous reporting systems. Combining data exploration, machine learning, and computational intelligence techniques with different sources of data from medical professionals, patient-generated results, electronic medical files, and social media is becoming a potent strategy to improve ADR detection, anticipate risks, and maximize patient safety.. Proactive safety inspection and pharmacovigilance are further made possible by patient-centered approaches and continual tracking via wearable technology and mobile health (mHealth). This review emphasizes the significance of risk-benefit analysis, the current approaches and difficulties in ADR monitoring, and the revolutionary potential of statistical pharmacovigilance. Advanced analytics-backed integration of professional and individual patient data holds promise for enhancing signal detection, assisting clinical decision-making, and fortifying regulatory procedures globally.

**KEYWORDS:**Introduction,Adr Data Source,Risk–Benefit Assessment,Data Mining In Pharmacovigilance,.Challenges,.Future Perspectives, References.

## 1. INTRODUCTION

### Definition and Significance of ADRs in Clinical Practice

Any unanticipated, detrimental reaction to a medication given at recommended dosages for disease prevention, diagnosis, or treatment is referred to as an adverse drug reaction (ADR) [1]. Because ADRs increase morbidity, mortality, and healthcare costs globally, they pose a serious public health concern [2,3]. ADRs are thought to be responsible for 5–10% of admitted patients in many settings, according to several studies [4–6].

### Role of Risk–Benefit Assessment in Therapeutic Decision-Making

Assessing a drug's possible therapeutic benefits in relation to its risks, such as adverse drug reactions, is known as risk-benefit analysis [7]. In order to guarantee patient safety, direct clinical judgment, and provide information for post-marketing surveillance and regulatory approval, this procedure is essential [8]. Clinicians can tailor treatment with a comprehensive risk-benefit analysis, particularly for groups at increased risk of adverse drug reactions (ADRs), such as elderly patients or patients with several comorbidities [9].

### Traditional Methods for Monitoring ADRs

Clinical trials, hospital-based surveillance programs, and spontaneous reporting systems (SRS) have all been used in the past for ADR monitoring [10]. For post-marketing pharmacovigilance, spontaneous reporting platforms like the FDA Hazardous Event Monitoring Mechanism (FAERS), EudraVigilance and the World Health Organization's VigiBase are frequently utilized [11]. These systems have drawbacks like underreporting, delayed reporting, and a lack of common thread data (drug exposure), despite their effectiveness in identifying serious and unique ADRs [12,13].

**Challenges in Capturing Comprehensive ADR Data**

Comprehensive ADR monitoring is hampered by a number of issues. These include limited patient follow-up, inconsistent or incomplete reporting, and variations in data quality among sources [14]. Conventional reporting systems frequently overlook ADRs with delayed onset or extremely rare events [15]. Furthermore, accurate identification of signals and reliable risk assessment are made more difficult by the heterogeneity of data sources, which includes variations in coding systems, vocabulary, and data structures [16].

**Justification for Combining Patient-Reported Data with Healthcare Professional Data**

ADR characterization and detection can be improved by combining data from patients and healthcare providers [17]. While patients may provide insights into actual-world drug tolerability, discomfort trajectories, adherence issues, and quality-of-life impacts, medical personnel provide empirically validated reports [18].Enhancing signal detection, improving risk projections, and ultimately improving patient safety can be achieved by integrating multiple sources of data using contemporary data mining, the processing of natural language (NLP), and artificial intelligence (AI) techniques [19,20].

**2. ADR DATA SOURCE**

**Hospital databases and spontaneous**

By reporting suspected adverse drug reactions (ADRs) to systems such as FAERS, EudraVigilance, and andVigiBase, which compile reports from clinicians, pharmacists, and different medical staff, health care workers play a crucial part in pharmacovigilance [11,21]. These systems aid in the early identification of uncommon or novel ADRs. Hospital databases, including electronic physician records, pharmacy records, and lab data, are also rich organization data sources that document medications, lab results, and observed adverse drug reactions. These databases can be used for epidemiological analyses and signal detection [22].

**Clinical Trials and Post-Marketing Surveillance**

Clinical trials offer a controlled setting for ADR detection and are intended to assess a drug's safety and effectiveness prior to regulatory approval. However, trials' capacity to identify uncommon or chronic ADRs is limited by their frequent small participant sizes, stringent inclusion criteria, and brief follow-up [23]. By tracking drug safety in bigger and more diverse populations over longer periods of time, post-marketing surveillance enhances pre-approval studies by identifying practical safety signals [10,12].




Figure 1: Essential information for reporting adverse drug reactions according to MHRAguidelines.

**Platforms for self-reporting and patient registries**

Patients can directly report adverse drug reactions (ADRs) through patient registries and independent platforms (e.g., FDA

MedWatch consumer reporting, UK Yellow Card Scheme) [24]. These systems offer distinct perspectives on patient-centered outcomes, symptom progression over time, and medication tolerability that might not be included in physician reports.

**Social Media and Patient Forums**

Near real-time knowledge about feedback from patients and drug-related complaints is provided by social media websites and online patient forums. Researchers can identify new safety trends more quickly than with traditional systems by using text mining and natural language processing (NLP) to extract ADR signals from unstructured posts [19,25].

**Advantages and Drawbacks In contrast to expert reports**

By documenting subjective experiences, initial signs, and adherence-related problems, patient-reported data supplement expert reports. Nevertheless, these data may be less reliable due to reporting bias, errors, and a lack of clinical proof [18,24]. As a result, combining data from patients and clinicians can enhance the overall efficacy of pharmacovigilance systems as well as both the specificity and sensitivity of signal detection.

## 3. RISK–BENEFIT ASSESSMENT

**Concept and Methods (Quantitative and Qualitative Approaches)**

The process of methodically weighing a drug's possible therapeutic benefits against its risks—particularly adverse drug reactions—is known as risk-benefit assessment [7]. To provide objective indicators of benefit vs. risk, quantitative approaches use statistical and mathematical frameworks such as Bayesian benefit–risk modeling, hazard ratios, number needed to treat (NNT), and number needed to harm (NNH) [8]. To evaluate the clinical significance, seriousness, and acceptability of risks in relation to benefits, qualitative methods employ multi-criteria decision analysis (MCDA), structured decision frameworks, and expert judgment [26]. A thorough foundation for decision-making in medical care and regulatory contexts is provided by a hybrid that combines the two approaches.

**Incorporating ADR Data into Risk–Benefit Analysis**

ADRs are a fundamental component of risk-benefit analyses. The frequency, severity, timing of onset, and recovery capacity of adverse events are measured by analyzing data from SRS, clinical research, after-marketing monitoring, and patient-reported outcomes. Risk magnitude is evaluated with the aid of metrics like incidence rate, percentage of risk, and hazard ratio. Clinicians and regulatory agencies can enhance patient safety by incorporating ADR data to optimize dosage schedules, implement risk mitigation techniques (black box warnings, screening), or update labeling.

**Case Studies or Examples of Therapeutic Decision-Making**

Examples from real-world situations show how risk-benefit analysis can be used practically. For example, when using warfarin therapy, doctors have to weigh the advantages of the anticoagulant against the risk of bleeding, modifying dosage and keeping an eye on INR according to risk factors unique to each patient. Another example of structured risk-benefit considerations is the use of isotretinoin, a medication, for severe acne in conjunction with a strong pregnancy-prevention program to reduce teratogenic risk. These illustrations highlight how crucial ADR data is for guiding customized treatment plans and medical judgments.



Case Studies or Examples of Therapeutic Decision-Making

| Case Study | Therapeutic Decision |
|---|---|
| 1. Patient with hypertension and a history of coronary artery disease | Initiate antihypertensive therapy with a beta-blocker |
| 2. Patient with type 2 diabetes and chronic kidney disease | Prescribe an SGLT2 inhibitor to control blood glucose and reduce cardiovascular risk |
| 3. Patient with chronic migraine unresponsive to first-line treatments | Consider prescribing a CGRP inhibitor |

Figure 2: Factors influencing adverse drug reactions and their clinical outcomes.

**Regulatory Views and Guidelines**

Structured risk-benefit analyses are required by regulatory bodies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) as part of the post-approval and drug approval procedures [8,27]. Standardized frameworks for

comparing risks and benefits are offered by guidelines such as ICH E2C(R2) and EMA's Good Regulatory Practices (GVP) Module VII.




Figure 3: Factors influencing adverse drug reactions and their clinical outcomes.

## 4. DATA MINING IN PHARMACOVIGILANCE

### Signal Detection Algorithms (Disproportionality Analysis, Bayesian Methods)

To find possible ADR signals in sizable pharmacovigilance databases, data mining techniques are crucial. Disproportionality analysis (DPA) techniques use metrics like the reported odds ratio (ROR), proportionate the reported ratio (PRR), and the information component (IC) to compare the observed and expected numbers of drug-event pairs in order to identify anomalous reporting patterns [28]. Statistical estimates of ADR signals are produced by Bayesian techniques, like the Bayesian Confidence Propagated Neural Network (BCPNN), which may improve the accuracy of detection in sparse datasets.

### Artificial Intelligence and Machine Learning Methods

In pharmacovigilance, algorithmic learning (ML) and artificial intelligence (AI) techniques are being used more and more for identification of patterns and predictive modeling. Random forests, aid vector machines, and gradient boosting are examples of supervised machine learning algorithms that have been applied to group ADRs and forecast risk [11,29].ADR data can be extracted from unstructured text in patient forums, social media, and clinical notes using NLP, or natural language processing [19]. Convolutional neural networks and recurrent neural networks are two examples of deep learning models that have shown excellent performance in identifying intricate ADR patterns in a variety of datasets [30].

### Integrating Data from Professionals and Patients

The contextual understanding of ADRs is improved and signal detection is improved by incorporating clinician and patient-reported data. While patient reports include early onset indicators and real-world symptom trajectories, clinician reports are typically structured and validated. A more thorough drug safety profile results from the complemented nature of the above information sources.

### Difficulties with Data Quality and Standardization

Issues with multi-source integration include inconsistent coding schemes, noisy or missing data, and inconsistent report quality. Dataset harmonization is facilitated by standardization through data models (e.g., OMOP Common Data Model) and controlled vocabularies (e.g., MedDRA, SNOMED CT) [31].

### Successful Application Examples

Numerous studies provide examples of successful multi-source data mining. In order to identify new drug–ADR associations sooner than with SRS alone, Harpaz et al. (2012) integrated FAERS data with the medical literature. Analyses of data from social media and forums have also revealed side effects (for example, statins and antidepressants) before traditional reporting. Finding

ADR patterns that guide clinical recommendations and regulatory decisions has also been made possible by the integration of electronic medical records (EHRs), billing data, and patient registers [11,32].

## 5. CHALLENGES

### Biases in Reporting and Underreporting

Pharmacovigilance is still severely limited by underreporting, as traditional systems only record a small percentage of ADRs (estimates range from 6 to 10%) [12,33]. Due to time limitations, a lack of certainty regarding causality, or the belief that what happened is already known, clinicians may neglect to report. The completeness and reliability of patient-reported ADRs can be diminished by recall bias, partial disclosure of serious manifestations, or misattribution.




Figure 4: Major challenges in pharmacovigilance and ADR monitoring.

### Privacy Issues and Data Heterogeneity

Standardizing and combining ADR data is difficult due to the heterogeneity of data sources, which include SRS, EHRs, claims spreadsheets, and unstructured media [16]. Inconsistent analyses may arise from variations in data formats, coding schemes, and terminology. Access to comprehensive patient-level data is restricted by privacy and regulatory laws (such as HIPAA and GDPR), which makes cross-institutional data sharing and large-scale analyses more difficult.

### Verification of Patient-Reported Results

ADR incidence may be overestimated or false signals may result from patient-reported outcomes (PROs), which provide useful real-world insights but frequently lack clinical verification and may contain misreporting or symptom misattribution. Data validity is increased through the use of digital health tools, standardized questionnaires, and cross-referencing with reports from clinicians.

### Problems with Database Interoperability

Multi-source data integration is hampered by interoperability issues, which are caused by variations in database structures, vocabulary sets, and metadata standards. Harmonization is aided by the adoption of controlled languages such as the MedDRA, SNOMED, CT, and universal data models (like OMOP), but there is a lack of consistent implementation amongst institutions. Interoperability issues can hinder prompt clinical or regulatory action, delay signal detection, and lower analytical accuracy.

## 6. FUTURE PERSPECTIVES

### Predictive models and advanced AI for ADR detection

By detecting ADR signals more quickly and precisely than with conventional methods, AI and mathematical modeling are predicted to revolutionize pharmacovigilance. Large, diverse datasets can be handled by machine learning, which includes deep training and ensemble approaches, which can also identify subtle drug-event correlations [11]. Real-time extraction of unstructured sources (such as patient forums and clinical notes) for ADR detection is made possible by combining AI and NLP [19].

### Integration of Wearable Technology and Mobile Health (mHealth) for Real-Time Monitoring

Patients' physiological parameters (such as heartbeat, blood pressure, levels of glucose, activity, and sleep) can be continuously monitored by wearable technology and mobile health apps. These parameters can be linked to drug exposure to identify adverse drug reactions (ADRs) almost instantly. Outside of conventional clinical settings, these tools also encourage proactive reporting and patient involvement.

### Methods of Patient-Centric Pharmacovigilance

Patient-centric pharmacovigilance prioritizes safety monitoring by focusing on patients' reported outcomes, preferences, and experiences. Digital tools and direct patient reporting platforms enable patients to self-report adverse drug reactions, treatment outcomes, and quality-of-life effects. A more comprehensive and patient-relevant safety assessment is produced when these insights are combined with clinician data.

### International Cooperation and Harmonization of Regulations

For better pharmacovigilance, international cooperation between regulatory bodies, medical institutions, and scholarship networks is crucial. Standardized ADR reporting, collaboration on data, and methodological consistency are encouraged by programs like the WHO Programme for Worldwide Drug Monitoring and public-private initiatives like WEB-RADR. International safety decision-making is accelerated, signal detection is strengthened, and multi-source data integration is made easier by the convergence of regulations on guidelines, vocabulary, and data standards.

## CONCLUSION :

Risk-benefit analysis and adverse drug effects (ADR) monitoring are still essential elements of pharmacovigilance, guaranteeing patient safety and well-informed treatment choices .Underreporting, delays, and insufficient coverage of real-world populations are the drawbacks of traditional methods, such as natural systems of reporting, research studies, and post-marketing surveillance, which have nevertheless produced crucial safety data . ADR detection is made more sensitive, thorough, and timely by integrating data from several sources, such as social media, electronic health records, patient-reported outcomes, and reports from medical professionals . Proactive risk management and increased predicted accuracy are made possible by the analysis of these diverse datasets using advanced data mining, machine learning, and computational intelligence approaches . Patients are empowered to report safety incidents and pharmacovigilance capabilities are further expanded by patient-centric methodologies and real-time monitoring using wearable technology and mobile health (mHealth) .Future studies should concentrate on creating globally unified frameworks for pharmacovigilance, confirming patient-reported outcomes, and standardizing the integration of data from several sources . Clinically, implementing AI-driven signal detection and predictive models can optimize treatment, promote prompt interventions, and lower ADR-related death and morbidity . The advancement of medication safety and public health will depend on bolstering international cooperation, regulation collaboration, and evidence-based risk-benefit analysis .

## References


1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet*. 2000;356(9237):1255–9.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA*. 1998;279(15):1200–5.
3. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. *J PharmacolPharmacother*. 2013;4(Suppl 1):S73–7.
4. Stausberg J, et al. Drug-related admissions and hospital-acquired adverse drug events: an observational study. *BMC Health Serv Res*. 2011;11:134.
5. Giardina C, et al. Adverse drug reactions in hospitalized patients: Impact on length of stay and mortality. *Front Pharmacol*. 2018;9:350.
6. Seo B, et al. Incidence and Economic Burden of Adverse Drug Reactions. *J Korean Med Sci*. 2023;38:e56.
7. European Medicines Agency / ICH. Guideline on good pharmacovigilance practices (GVP). EMA; 2020.
8. International Council for Harmonisation. ICH E2C(R2) guideline — periodic benefit–risk evaluation report. ICH; 2022.
9. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. *Br J Clin Pharmacol*. 2004;57(2):121–6.
10. Waller PC, Evans SJW. A model for the future conduct of pharmacovigilance. *Pharmacoepidemiol Drug Saf*. 2003;12(1):17–29.
11. Warner J, et al. Artificial Intelligence: Applications in Pharmacovigilance. *Drug Saf*. 2025.

12. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. *Drug Saf*. 2006;29(5):385–96.
13. Härmark L, van Grootheest AC. Pharmacovigilance: Methods, recent developments and future perspectives. *Eur J Clin Pharmacol*. 2008;64(8):743–52.
14. Lopez-González E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions. *Drug Saf*. 2009;32(1):19–31.
15. Sarker A, et al. Utilizing social media data for pharmacovigilance: a review. *J Biomed Inform*. 2015;54:202–12.
16. Cioms Working Group / EMA. AI in pharmacovigilance: CIOMS draft report. 2025.
17. Avery AJ, et al. Patient reporting of adverse drug reactions: a review of published literature and international experience. *Br J Clin Pharmacol*. 2011;72(5):731–8.
18. van Hunsel F, et al. The contribution of patient reports to signals of adverse drug reactions: a mixed-methods study. *Drug Saf*. 2012;35(12):1159–69.
19. Algarvio RC, et al. Artificial intelligence in pharmacovigilance: streamlining signal detection and ADR reporting. *J PharmacolToxicol Methods*. 2025.
20. Harpaz R, et al. Data mining and signal detection in spontaneous reporting systems for adverse drug events. *Clin Pharmacol Ther*. 2012;91(6):1010–21.
21. U.S. FDA. FDA Adverse Event Reporting System (FAERS). Silver Spring, MD; 2022.
22. Dimitsaki S, et al. Applying AI to structured real-world data for pharmacovigilance. *J Med Internet Res*. 2024.
23. Pirmohamed M, et al. Adverse drug reactions as cause of admission to hospital. *BMJ*. 2004;329(7456):15–9.
24. Yellow Card Scheme (UK); FDA MedWatch consumer reporting.
25. Sarker A, et al. Mining ADR signals from social media posts. *J Biomed Inform*. 2015.
26. Multi-criteria decision analysis in regulatory benefit–risk assessment literature.
27. EMA GVP Module VII / FDA benefit–risk guidance.
28. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. *Pharmacoepidemiol Drug Saf*. 2009.
29. Warner J, et al. AI in pharmacovigilance and signal management. *Drug Saf*. 2025.
30. Mohsen A, Tripathi L, Mizuguchi K. Deep learning prediction of adverse drug reactions using Open TG-GATEs and FAERS. *arXiv*. 2020.
31. OMOP Common Data Model, MedDRA, SNOMED CT standards.
32. Harpaz R, et al. Integration of literature and spontaneous reporting for new ADR discovery. *Clin Pharmacol Ther*. 2012.
33. Hazell & Shakir: underreporting rates in pharmacovigilance.